AVP and pulmonary arterial hypertension: In PAH, copeptin had a statistically significant correlation with NYHA class, 6MWT, and renal function, and its plasma levels were significantly lower after initiating PAH-specific therapy; it was also associated with shorter survival (p  <  0.001) in a study published in 2013 [102].